Adjuvant nivolumab (NIVO) versus ipilimumab (IPI) in resected stage III/IV melanoma: 3-year efficacy and biomarker results from the phase III CheckMate 238 trial
Main Authors: | , , , , , , , , , , , , , , , , , , , |
---|---|
格式: | Conference item |
語言: | English |
出版: |
Oxford University Press
2019
|